Florida is currently home to 3774 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Recruiting
The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: University of Miami - Converge Miami Building, Miami, Florida
Conditions: Pre-Exposure Prophylaxis of HIV Infection
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Recruiting
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: BRCR Global, Weston, Florida
Conditions: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
Recruiting
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/14/2025
Locations: Research Site, Stuart, Florida
Conditions: Non-small Cell Lung Cancer
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Recruiting
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/14/2025
Locations: Meris Clinical Research-310 Oakfield Dr- Site Number : 115, Brandon, Florida
Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Recruiting
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone ar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Recruiting
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/14/2025
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida
Conditions: Breast Cancer
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Recruiting
The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Bay Pines VA Healthcare System, Bay Pines, Florida
Conditions: Non-muscle-invasive Bladder Cancer
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Recruiting
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
05/14/2025
Locations: Nemours Children's Health Center, Jacksonville, Florida
Conditions: Puberty; Precocious, Central
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Recruiting
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib or other Janus Kinase (JAK) inhibitors in participants with MF in Part 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: University of Miami, Coral Gables, Florida
Conditions: Myelofibrosis
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Nature Coast Clinical Research, LLC, Inverness, Florida
Conditions: NASH
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Recruiting
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with invasive fungal infection (IFI).
Gender:
ALL
Ages:
Between 1 day and 2 years
Trial Updated:
05/14/2025
Locations: Nicklaus Children's Hospital ( Site 2109), Miami, Florida
Conditions: Invasive Fungal Infection